Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed
first‑participant dosing in an Australia Phase I/II study today. Preclinical
data show strong inhibition in tumor cells and xenograft models with diverse RAS
mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic,
non‑small‑cell lung and colorectal cancers, and report favorable
pharmacokinetics and safety.
